Neurocrine Biosciences (NASDAQ:NBIX) Stock Price Target Raised at Guggenheim

Neurocrine Biosciences (NASDAQ:NBIX) had its price target boosted by investment analysts at Guggenheim from $207.00 to $224.00 in a report released on Wednesday, Benzinga reports. The firm presently has a “buy” rating on the stock. Guggenheim‘s price target would suggest a potential upside of 37.67% from the company’s previous close.

NBIX has been the topic of a number of other research reports. Zacks Research lowered shares of Neurocrine Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, August 4th. Canaccord Genuity Group raised their price objective on shares of Neurocrine Biosciences from $210.00 to $220.00 and gave the stock a “buy” rating in a research note on Tuesday. TD Cowen lifted their price objective on shares of Neurocrine Biosciences from $200.00 to $220.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Royal Bank Of Canada lifted their price objective on shares of Neurocrine Biosciences from $187.00 to $190.00 and gave the stock an “outperform” rating in a research report on Tuesday. Finally, Cantor Fitzgerald boosted their target price on shares of Neurocrine Biosciences from $210.00 to $215.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have given a Hold rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $202.32.

Neurocrine Biosciences Price Performance

NASDAQ NBIX traded down $2.14 on Wednesday, hitting $162.71. 244,883 shares of the company were exchanged, compared to its average volume of 1,229,311. Neurocrine Biosciences has a twelve month low of $122.14 and a twelve month high of $186.12. The firm has a market capitalization of $16.54 billion, a P/E ratio of 24.30, a price-to-earnings-growth ratio of 0.64 and a beta of 0.36. The company’s 50 day moving average price is $146.72 and its 200-day moving average price is $147.60.

Neurocrine Biosciences (NASDAQ:NBIX) last announced its earnings results on Monday, November 2nd. The company reported $3.29 EPS for the quarter, topping the consensus estimate of $1.91 by $1.38. Neurocrine Biosciences had a net margin of 18.98% and a return on equity of 24.11%. The company had revenue of $1.12 billion during the quarter, compared to analysts’ expectations of $1.04 billion. During the same period last year, the company posted $2.04 earnings per share. The business’s revenue for the quarter was up 41.3% on a year-over-year basis. As a group, equities analysts expect that Neurocrine Biosciences will post 7.72 EPS for the current year.

Insider Activity

In other news, Director George J. Morrow sold 7,500 shares of the company’s stock in a transaction dated Monday, November 2nd. The stock was sold at an average price of $145.79, for a total value of $1,093,425.00. Following the transaction, the director owned 10,386 shares in the company, valued at $1,514,174.94. This represents a 41.93% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Matt Abernethy sold 2,311 shares of the stock in a transaction that occurred on Monday, September 14th. The stock was sold at an average price of $157.20, for a total transaction of $363,289.20. Following the completion of the sale, the chief financial officer directly owned 42,808 shares of the company’s stock, valued at $6,729,417.60. This trade represents a 5.12% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 18,137 shares of company stock worth $2,829,332 in the last 90 days. Company insiders own 4.60% of the company’s stock.

Institutional Investors Weigh In On Neurocrine Biosciences

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Entrust Financial LLC increased its stake in shares of Neurocrine Biosciences by 62.9% in the third quarter. Entrust Financial LLC now owns 202 shares of the company’s stock worth $29,000 after acquiring an additional 78 shares during the last quarter. Raleigh Capital Management Inc. raised its holdings in shares of Neurocrine Biosciences by 561.8% during the third quarter. Raleigh Capital Management Inc. now owns 225 shares of the company’s stock worth $32,000 after acquiring an additional 191 shares in the last quarter. Basecamp Wealth Advisors LLC raised its holdings in shares of Neurocrine Biosciences by 582.9% during the first quarter. Basecamp Wealth Advisors LLC now owns 239 shares of the company’s stock worth $31,000 after acquiring an additional 204 shares in the last quarter. Cassaday & Co Wealth Management LLC acquired a new stake in Neurocrine Biosciences during the first quarter valued at $33,000. Finally, TrinityBridge Ltd acquired a new stake in Neurocrine Biosciences during the second quarter valued at $45,000. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Trending Headlines about Neurocrine Biosciences

Here are the key news stories impacting Neurocrine Biosciences this week:

• Positive Sentiment: Third-quarter revenue rose 41% year over year to $1.12 billion, beating estimates; earnings of $3.29 per share also topped consensus. Product sales exceeded $1 billion for the first time, and Neurocrine raised its 2026 INGREZZA sales outlook to $2.9–$2.925 billion. Q3 results and guidance
• Positive Sentiment: Several analysts raised their price targets after the results, including Canaccord to $220, Piper Sandler to $215 and RBC to $190. Their ratings were mostly positive, though Morgan Stanley maintained an equal-weight rating.
• Positive Sentiment: Neurocrine has started a Phase 2 Alzheimer’s study, adding a pipeline development to the near-term commercial growth story. Alzheimer’s study update
• Neutral Sentiment: A report flagged integration challenges and legacy liabilities as risks to Neurocrine’s ability to realize value from its Soleno acquisition. Soleno acquisition risks
• Negative Sentiment: Director George J. Morrow reported selling shares in several transactions. The sales were made under a pre-arranged Rule 10b5-1 plan, which may temper the signal, but insider selling can weigh on sentiment.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is a San Diego-based biopharmaceutical company focused on discovering, developing and commercializing medicines for neurological, neuroendocrine and psychiatric disorders. The company’s research programs target conditions in which treatments may address significant unmet medical needs.

Neurocrine’s leading product is INGREZZA (valbenazine), a vesicular monoamine transporter 2 inhibitor approved in the United States for the treatment of tardive dyskinesia and chorea associated with Huntington’s disease.